BMS scores again this year with the announcement that the FDA has approved its new drug Nulojix (belatacept) for the prevention of kidney transplant rejections. This comes on the heels of BMS' Yervoy (ipilumumab) receiving approval for the treatment of melanoma just a few months ago.
Nulojix is the first new kidney anti-rejection drug to be approved in more than 10 years. It is a T-cell costimulation blocker to mitigate the bodies immune response. It is designed to be used with other immunosuppressants like corticosteroids. Analysts are projecting peak sales for the drug in the $300 M to $500 M range. See Fierce Biotech and Xconomy.
Posted by Bruce Lehr June 16th 2011.
Comments